Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting


VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

View original post here:
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

Related Posts